Acute Myeloid Leukemia Clinical Trial
Official title:
Assessing Feasibility of Expansion and Characterization of Gamma Delta T Cells From Peripheral Blood and Bone Marrow of Patients With Acute Myeloid Leukaemia as Starting Product for Generation of CD33-CD28 Gamma Delta T Cells
The Royal Marsden NHS Foundation Trust is committed to improving patient experience; this
research is being undertaken to try to develop a novel treatment for patients with Acute
Myeloid Leukaemia (AML). Researchers aim to develop a new therapy which uses a patient's own
immune cells called T cells to treat AML. In this study, numbers and properties of T cells
which can be collected from the blood of patients with AML at various points throughout their
treatment will be investigated. Blood samples will be collected at the same time as the
patient's bone marrow test.
If patients need further bone marrow tests during their course of treatment to assess the
status of disease, the research team would ask that additional samples are taken at the same
time as the bone marrow and blood will be collected at the same time as the routine blood
draw.
Following collection of blood samples, they will be used to purify a population of blood
cells called Gamma Delta T cells which have been shown to have a potential role in control of
cancers. In addition the researchers plan to determine whether it is possible to put a novel
receptor called a chimeric antigen receptor (CAR) to potentially directly target leukaemia
cells. Currently this is only an exploratory study and none of the samples collected will be
used for treatment and is only to assess whether or not this strategy is feasible. This may
however lead on to studies in the future looking at the safety and effectiveness of this
strategy. This hopefully will lead in the future to improvements in treatment and outcome for
patients with AML.
If patients need further bone marrow tests during their course of treatment to assess the
status of disease, the research team would ask that additional samples are taken at the same
time as the bone marrow and blood will be collected at the same time as the routine blood
draw.
Following collection of blood samples, they will be used to purify a population of blood
cells called Gamma Delta T cells which have been shown to have a potential role in control of
cancers. In addition the researchers plan to determine whether it is possible to put a novel
receptor called a chimeric antigen receptor (CAR) to potentially directly target leukaemia
cells. Currently this is only an exploratory study and none of the samples collected will be
used for treatment and is only to assess whether or not this strategy is feasible. This may
however lead on to studies in the future looking at the safety and effectiveness of this
strategy. This hopefully will lead in the future to improvements in treatment and outcome for
patients with AML.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
| Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
| Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
| Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
| Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
| Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
| Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
| Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
| Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
| Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |